Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)

NCT02736240 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2760

Enrollment

INDUSTRY

Sponsor class

Conditions

Diseases Caused by Streptococcus Pneumoniae Serotypes

Interventions

BIOLOGICAL: 7-valent pneumococcal conjugate vaccine
BIOLOGICAL: 13-valent pneumococcal polysaccharide conjugate vaccine

Sponsor

Walvax Biotechnology Co., Ltd.